Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (908 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on gamma-aminobutyric acid mediated synaptic transmission.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Benzylpenicillin; Penicillin G Sodium; Sodium Benzylpenicillin; Sodium Penicillin; Pfizerpen; Ursopen; Penicillin G Potassium; Benzylpenicillin Potassium.
Where it fits in the MeSH classification
- Broader topics
- Penicillins
- Narrower topics
- Ampicillin; Carbenicillin; Penicillin G Benzathine; Penicillin G Procaine; Sulbenicillin
Related concepts
- Gamma-Aminobutyric Acid
Research landscape
PubMed indexes 43,785 records tagged with the MeSH heading “Penicillin G” (counts retrieved 2026-10-31). 4,857 of them (11.1%) were published from 2020 onward, and the busiest period so far is through 1999 with 25,628 records.
Reviews account for 2,316 records (5.3%) and meta-analyses for 300. Randomized controlled trials number 3,896 (8.9%) as a share of all records on the topic. Randomized trials make up a comparatively large share of this literature, which means many treatment questions have been tested directly.
Show the data
| Period | Records |
|---|---|
| through 1999 | 25,628 |
| 2000-2009 | 6,224 |
| 2010-2019 | 7,076 |
| 2020 onward | 4,857 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 2,316 | 5.3% |
| Meta-analyses | 300 | 0.7% |
| Randomized controlled trials | 3,896 | 8.9% |
Method: PubMed query "Penicillin G"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in drugs and chemicals
Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Effects of different amoxicillin treatment durations on microbiome diversity and composition in the gut | 2022 | Research article Design not recorded in structured metadata | 29 | cc by PMID 36301847 · DOI · PMC9612567 |
| Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam | 2022 | Research article Design not recorded in structured metadata | 25 | cc by PMID 35114945 · DOI · PMC8812189 |
| Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance | 2024 | Research article Design not recorded in structured metadata | 24 | cc by PMID 38918379 · DOI · PMC11199616 |
| Evaluating the duration of post-discontinuation therapeutic ampicillin exposures in preterm infants | 2026 | Research article Design not recorded in structured metadata | 2 | cc by PMID 41826670 · DOI · PMC13290478 |
Effects of different amoxicillin treatment durations on microbiome diversity and composition in the gut [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Antibiotics seize an effect on bacterial composition and diversity and have been demonstrated to induce disruptions on gut microbiomes.
- Closing excerpt
- This may strengthen the argument for shorter antibiotic treatment regimens to both limit the emergence of antibiotic resistance and risk of gut microbiome disturbance.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (343 words)
Antibiotics seize an effect on bacterial composition and diversity and have been demonstrated to induce disruptions on gut microbiomes. This may have implications for human health and wellbeing, and an increasing number of studies suggest a link between the gut microbiome and several diseases. Hence, reducing antibiotic treatments may be beneficial for human health status. Further, antimicrobial resistance (AMR) is an increasing global problem that can be counteracted by limiting the usage of antibiotics. Longer antibiotic treatments have been demonstrated to increase the development of AMR. Therefore, shortening of antibiotic treatment durations, provided it is safe for patients, may be one measure to reduce AMR. In this study, the objective was to investigate effects of standard and reduced antibiotic treatment lengths on gut microbiomes using a murine model. Changes in the murine gut microbiome was assessed after using three different treatment durations of amoxicillin (3, 7 or 14 days) as well as a control group not receiving amoxicillin. Fecal samples were collected before and during the whole experiment, until three weeks past end of treatment. These were further subject for 16S rRNA Illumina MiSeq sequencing. Our results demonstrated significant changes in bacterial diversity, richness and evenness during amoxicillin treatment, followed by a reversion in terms of alpha-diversity and abundance of major phyla, after end of treatment. However, a longer restitution time was indicated for mice receiving amoxicillin for 14 days, and phylum Patescibacteria did not fully recover. In addition, an effect on the composition of Firmicutes was indicated to last for at least three weeks in mice treated with amoxicillin for 14 days. Despite an apparently reversion to a close to original state in overall bacterial diversity and richness, the results suggested more durable changes in lower taxonomical levels. We detected several families, genera and ASVs with significantly altered abundance three weeks after exposure to amoxicillin, as well as bacterial taxa that appeared significantly affected by amoxicillin treatment length. This may strengthen the argument for shorter antibiotic treatment regimens to both limit the emergence of antibiotic resistance and risk of gut microbiome disturbance.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36301847 · DOI · PMC9612567
Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam [2]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundAmoxicillin-resistant Helicobacter pylori (H.
- Closing excerpt
- Additional studies are necessary to identify the mechanisms contributing to this resistance in Vietnam.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (322 words)
BackgroundAmoxicillin-resistant Helicobacter pylori (H. pylori) strains seem to have increased over time in Vietnam. This threatens the effectiveness of H. pylori eradication therapies with this antibiotic. This study aimed to investigate the prevalence of primary resistance of H. pylori to amoxicillin and to assess its association with pbp1A point mutations in Vietnamese patients.Materials and methodsNaive patients who presented with dyspepsia undergoing upper gastrointestinal endoscopy were recruited. Rapid urease tests and PCR assays were used to diagnose H. pylori infection. Amoxicillin susceptibility was examined by E-tests. Molecular detection of the mutant pbp1A gene conferring amoxicillin resistance was carried out by real-time PCR followed by direct sequencing of the PCR products. Phylogenetic analyses were performed using the Tamura-Nei genetic distance model and the neighbor-joining tree building method.ResultsThere were 308 patients (46.1% men and 53.9% women, p = 0.190) with H. pylori infection. The mean age of the patients was 40.5 ± 11.4 years, ranging from 18 to 74 years old. The E-test was used to determine the susceptibility to amoxicillin (minimum inhibitory concentration (MIC) ≤ 0.125 μg/ml) in 101 isolates, among which the rate of primarily resistant strains to amoxicillin was 25.7%. Then, 270 sequences of pbp1A gene fragments were analysed. There were 77 amino acid substitution positions investigated, spanning amino acids 310-596, with the proportion varying from 0.4 to 100%. Seven amino acid changes were significantly different between amoxicillin-sensitive (AmoxS) and amoxicillin-resistant (AmoxR) samples, including Phe366 to Leu (p 414 to Arg (p 464-465 (p = 0.009), Val469 to Met (p = 0.021), Phe473 to Val (p 479 to Glu (p = 0.044), and Ser/Ala/Gly595-596 (p = 0.001). Phylogenetic analyses suggested that other molecular mechanisms might contribute to amoxicillin resistance in H. pylori in addition to the alterations in PBP1A.ConclusionsWe reported the emergence of amoxicillin-resistant Helicobacter pylori strains in Vietnam and new mutations statistically associated with this antimicrobial resistance. Additional studies are necessary to identify the mechanisms contributing to this resistance in Vietnam.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 35114945 · DOI · PMC8812189
Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance [3]
Abstract reading summary — source excerpts
- Opening excerpt
- The incidence of beta-lactam resistance among clinical isolates is a major health concern.
- Closing excerpt
- Our results reveal that combinations of distinct genetic mutations, accessible at large population sizes, can drive high-level resistance to ampicillin even independently of beta-lactamases.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (163 words)
The incidence of beta-lactam resistance among clinical isolates is a major health concern. A key method to study the emergence of antibiotic resistance is adaptive laboratory evolution. However, in the case of the beta-lactam ampicillin, bacteria evolved in laboratory settings do not recapitulate clinical-like resistance levels, hindering efforts to identify major evolutionary paths and their dependency on genetic background. Here, we used the Microbial Evolution and Growth Arena (MEGA) plate to select ampicillin-resistant Escherichia coli mutants with varying degrees of resistance. Whole-genome sequencing of resistant isolates revealed that ampicillin resistance was acquired via a combination of single-point mutations and amplification of the gene encoding beta-lactamase AmpC. However, blocking AmpC-mediated resistance revealed latent adaptive pathways: strains deleted for ampC were able to adapt through combinations of changes in genes involved in multidrug resistance encoding efflux pumps, transcriptional regulators, and porins. Our results reveal that combinations of distinct genetic mutations, accessible at large population sizes, can drive high-level resistance to ampicillin even independently of beta-lactamases.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38918379 · DOI · PMC11199616
Evaluating the duration of post-discontinuation therapeutic ampicillin exposures in preterm infants [4]
Abstract reading summary — source excerpts
- Opening excerpt
- ObjectiveDetermine if preterm infants have prolonged therapeutic post-discontinuation antibiotic exposures (PDAE) following empiric ampicillin.
- Closing excerpt
- Shorter courses could be considered.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (80 words)
ObjectiveDetermine if preterm infants have prolonged therapeutic post-discontinuation antibiotic exposures (PDAE) following empiric ampicillin.Study designProspective study of 27 infants ≤7 days and ResultAt 24- and 36-h after ampicillin, the probability of exposures ≥1 μg/mL was 95% and 60%, respectively. PDAE (≥1 μg/mL) lasted a median 33 h (95% confidence interval: 15, 79), and varied with GA, from median 53 h (ConclusionMany preterm infants experience therapeutic exposures at least 24 h after the final ampicillin dose. Shorter courses could be considered.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41826670 · DOI · PMC13290478
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Drug-induced liver injury [5]
- Research article Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis [6]
- Research article Treatment of syphilis: a systematic review [7]
- Research article Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage [8]
- Research article A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection [9]
- Research article Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail [10]
References
- Lekang K, Shekhar S, Berild D, Petersen FC, Winther-Larsen HC. Effects of different amoxicillin treatment durations on microbiome diversity and composition in the gut. . 2022. PMID 36301847 · DOI · PMC9612567
- Tran TT, Nguyen AT, Quach DT, Pham DT, Cao NM, Nguyen UT, et al.. Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam. . 2022. PMID 35114945 · DOI · PMC8812189
- Gross R, Yelin I, Lázár V, Datta MS, Kishony R. Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance. . 2024. PMID 38918379 · DOI · PMC11199616
- Boutzoukas AE, Le J, Kilpatrick R, Smith MJ, Laughon M, Gonzalez D, et al.. Evaluating the duration of post-discontinuation therapeutic ampicillin exposures in preterm infants. . 2026. PMID 41826670 · DOI · PMC13290478
- Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014. PMID 24388027 · DOI
- Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013. PMID 23074314 · DOI
- Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA. 2014. PMID 25387188 · DOI · PMC6690208
- Huttner A, Bielicki J, Clements MN, Frimodt-Møller N, Muller AE, Paccaud JP, et al.. Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage. Clin Microbiol Infect. 2020. PMID 31811919 · DOI
- Calvet X, Calvet X, García N, López T, Gisbert JP, Gené E, et al.. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000. PMID 10792124 · DOI
- Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002. PMID 12030945 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.